



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

November 11, 2021

BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

BSE Scrip Code: 506943

Stock Symbol: JBCHEPHARM

Dear Sir,

Sub: Outcome of meeting of Board of Directors – Unaudited Financial Results for the quarter ended September 30, 2021

In compliance with Regulation 30(2) and Regulation 33(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with circular no. CIR/CFD/CMD/4/2015 dated September 09, 2015, enclosed please find:

1. Unaudited standalone financial results for the quarter ended on September 30, 2021 accompanied by limited review report.
2. Unaudited consolidated financial results for the quarter ended on September 30, 2021 accompanied by limited review report.

These financial results have been approved and taken on record by the Board of Directors at its meeting held today, which commenced at 4:32 p.m. and concluded at 5.55 p.m.

We request you to take the above on record.

Thanking you,

Yours faithfully,

For J.B. Chemicals & Pharmaceuticals Ltd.

Sandeep Phadnis
Vice President - Secretarial
& Company Secretary

📍 **Registered Office:**
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

📍 **Corporate Office:**
Cnergy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

☎ +91 22 2439 5200 / 2439 5500
📠 +91 22 2431 5331 / 2431 5334
✉ info@jbcpl.com
🌐 www.jbcpl.com
CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 2021

(₹ in lakhs)

Sl.No.	Particulars	Quarter ended			Half Year ended		Year ended
		30/09/2021	30/06/2021	30/09/2020	30/09/2021	30/09/2020	31/03/2021
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from operations	52,672.69	54,630.13	41,177.85	1,07,302.82	90,140.28	1,89,199.55
2	Other income (Refer Note 5)	1,956.07	1,288.23	818.78	3,244.30	3,072.32	11,188.94
3	Total income (1+2)	54,628.76	55,918.36	41,996.63	1,10,547.12	93,212.60	2,00,388.49
4	Expenses						
	a. Cost of materials consumed	14,707.66	14,787.80	15,204.58	29,495.46	27,862.41	54,216.52
	b. Purchases of stock-in-trade	5,031.75	4,944.75	1,302.57	9,976.50	5,595.11	9,929.08
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,752.04)	(1,209.69)	(4,387.47)	(2,961.73)	(4,829.12)	(1,570.03)
	d. Employee benefits expense (Refer Note 3)	9,521.95	8,875.56	7,302.88	18,397.51	15,457.03	30,597.97
	e. Finance costs	118.44	88.54	169.59	206.98	542.71	719.18
	f. Depreciation and amortization expense	1,539.94	1,747.87	1,714.01	3,287.81	3,410.74	6,735.50
	g. Other expenses	13,695.02	11,401.29	11,181.64	25,096.31	19,665.68	40,389.47
	Total expenses (4)	42,862.72	40,636.12	32,487.80	83,498.84	67,704.56	1,41,017.69
5	Profit before tax (3-4)	11,766.04	15,282.24	9,508.83	27,048.28	25,508.04	59,370.80
6	Tax expenses						
	a. Current tax	2,700.00	3,800.00	2,355.00	6,500.00	6,100.00	13,750.00
	b. Deferred tax	226.05	(48.97)	55.52	177.08	117.20	912.32
	Total tax expense	2,926.05	3,751.03	2,410.52	6,677.08	6,217.20	14,662.32
7	Net Profit after tax (5-6)	8,839.99	11,531.21	7,098.31	20,371.20	19,290.84	44,708.48
8	Other comprehensive income						
	a. Items that will not be reclassified to profit or loss	(211.43)	(212.55)	(461.44)	(423.98)	(611.44)	(1,669.97)
	b. Income tax thereon	53.22	53.49	116.14	106.71	153.89	420.30
	Other Comprehensive income (net of tax)	(158.21)	(159.06)	(345.30)	(317.27)	(457.55)	(1,249.67)
9	Total comprehensive income after tax (7+8)	8,681.78	11,372.15	6,753.01	20,053.93	18,833.29	43,458.81
10	Paid up equity share capital (Face value of ₹ 2 each)	1,545.64	1,545.64	1,545.64	1,545.64	1,545.64	1,545.64
11	Other equity						1,79,100.45
12	Earnings per share (not annualised for the quarter and half year)						
	(1) Basic in ₹	11.44	14.92	9.18	26.36	24.96	57.85
	(2) Diluted in ₹	11.42	14.92	9.18	26.34	24.96	57.85

Notes:

- The above standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 11, 2021. The results of the Company are available for investors at www.jbcpl.com, www.nseindia.com and www.bseindia.com.
- This Statement has been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules, 2015 (as amended) (Ind AS), prescribed under Section 133 of the Companies Act, 2013, and other recognised accounting practices and policies, to the extent applicable.
- During the quarter, the Company has granted 26,04,258 stock options (comprising of 14,51,666 performance based stock options and 11,52,592 time based stock options) to employees and whole-time director(s) of the Company/ subsidiary company. The employee benefit expense for the quarter and half year ended September 30, 2021 includes charge of ₹ 1,316 lakhs towards equity-settled share-based payment transactions in terms of Ind AS 102 - 'Share-based Payment'.
- Subsequent to the quarter, the Company has granted 2,06,463 stock options (comprising of 1,21,095 performance based stock options and 85,368 time based stock options) to employees of the Company/ subsidiary Company.
- Other income for the year ended March 31, 2021 includes ₹ 1,977.24 lakhs being net profit on sale of an industrial land in the state of Maharashtra and ₹ 3,368.66 lakhs being consideration towards sale of one of the Company's product registration along with its marketing authorisation and trademark.
- Based on the internal and external information available up to the date of approval of these financial results by the Board of Directors, the Company continues to believe that the impact of Covid-19 on its business, assets, internal financial controls, profitability and liquidity, both present and future, would be limited and there is no indication of any material impact on the carrying amounts of inventories, tangible and intangible assets, investments, trade receivables and other financial assets. However, concerns of Covid-19 pandemic still continue and hence, the Company continues to follow necessary safety guidelines. The eventual outcome of the impact of the global health pandemic may be different from those estimated as on the date of approval of these financial results and the management will continue to closely monitor the changes to economic conditions in future and its impact on the Company.
- The Company has only one reportable business segment viz. "Pharmaceuticals".
- The figures for the previous period(s) have been re-grouped/reclassified, wherever necessary.

📍 **Registered Office:**
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

📍 **Corporate Office:**
Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

☎ +91 22 2439 5200 / 2439 5500
📠 +91 22 2431 5331 / 2431 5334
@ info@jbcpl.com
🌐 www.jbcpl.com
CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

9 STATEMENT OF STANDALONE ASSETS AND LIABILITIES AS AT SEPTEMBER 30, 2021.

(₹ in lakhs)

Particulars	As at September 30, 2021	As at March 31, 2021
	Unaudited	Audited
ASSETS		
(I) Non-current assets		
(a) Property, Plant and Equipment	56,407.02	54,227.21
(b) Capital work-in-progress	706.71	2,556.68
(c) Goodwill	431.92	431.92
(d) Other Intangible assets	1,799.25	1,801.25
(e) Financial Assets		
(i) Investments	14,606.68	14,587.55
(ii) Loans	102.49	54.90
(iii) Other financial assets	529.34	482.38
(f) Other non-current assets	595.23	106.89
Total non-current assets	75,178.64	74,248.78
(II) Current assets		
(a) Inventories	30,872.48	27,891.28
(b) Financial Assets		
(i) Investments	72,965.30	66,497.48
(ii) Trade receivables	45,472.47	37,410.81
(iii) Cash and cash equivalents	1,174.47	2,426.29
(iv) Bank balances other than (iii) above	230.86	216.62
(v) Loans	44.77	35.59
(vi) Others	401.00	981.16
(c) Current Tax Assets (Net)	2,220.44	1,683.83
(d) Other current assets	8,390.47	8,651.08
Total current assets	1,61,772.26	1,45,794.14
Total Assets	2,36,950.90	2,20,042.92
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share capital	1,545.64	1,545.64
(b) Other Equity	1,94,855.79	1,79,100.45
Total Equity	1,96,401.43	1,80,646.09
LIABILITIES		
(I) Non-current liabilities		
(a) Financial Liabilities		
Lease liabilities	2,080.50	514.14
(b) Provisions	2,044.03	1,257.14
(c) Deferred tax liabilities (Net)	6,446.97	6,376.60
(d) Other non-current liabilities	409.15	493.22
Total non-current Liabilities	10,980.65	8,641.10
(II) Current-liabilities		
(a) Financial Liabilities		
(i) Borrowings	2,644.10	2,643.28
(ii) Lease Liabilities	589.22	704.38
(iii) Trade payables		
A) Dues to Micro and Small Enterprises	1,217.16	1,309.55
B) Dues to Other than Micro and Small Enterprises	15,386.21	15,092.41
(iv) Other financial liabilities	4,741.30	6,563.43
(b) Other current liabilities	1,068.00	1,377.54
(c) Provisions	3,319.44	2,461.75
(d) Current Tax Liabilities (Net)	603.39	603.39
Total Current Liabilities	29,568.82	30,755.73
Total Equity and Liabilities	2,36,950.90	2,20,042.92

Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

Corporate Office:
Cnergy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500
+91 22 2431 5331 / 2431 5334
@ info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

10. Standalone Cash Flow Statement for the six months ended September 30, 2021

(₹ in lakhs)

Particulars	For the six months ended September 30, 2021		For the six months ended September 30, 2020	
	Unaudited		Unaudited	
A. Cash Flow from Operating Activities				
Profit before Tax		27,048.28		25,508.04
Adjustments For				
Depreciation and amortisation expense	3,287.81		3,410.74	
Unrealised Foreign Exchange Fluctuation (Net)	117.94		(132.00)	
Interest Expense	183.54		528.91	
Profit/loss on disposal/discard of Property, Plant and Equipment (Net)	(219.07)		70.97	
Profit on sale of Investments measured at FVTPL	(1,489.87)		(941.57)	
Net fair value gain on investments measured at FVTPL	(1,495.49)		(1,758.44)	
Interest Income	(17.88)		(135.21)	
Dividend Income	(0.50)		(0.50)	
Government Grant	(84.21)		(82.66)	
Re-measurement of defined benefit plan	(423.98)		(611.44)	
Excess provision written back	-		(223.09)	
Share based payment expense	1,316.24		-	
Discontinuance of Lease Assets	(14.23)		(7.19)	
		1,160.30		118.52
Operating Profit Before Working Capital Changes		28,208.58		25,626.56
Adjustments For				
Trade and other receivables	(7,560.44)		(6,870.44)	
Inventories	(2,981.20)		(8,884.01)	
Trade, other payables and provisions	409.56		2,960.28	
		(10,132.08)		(12,794.17)
Cash Generated From Operations		18,076.50		12,832.39
Direct Taxes Paid (net)		(7,036.61)		(4,599.77)
Net Cash from Operating Activities		11,039.89		8,232.62
B. Cash Flow from Investing Activities				
Payments for purchase of Property, plant and equipment	(3,451.89)		(2,413.89)	
Proceeds from disposal of Property, plant and equipment	750.93		0.30	
Payment for acquisition of a business undertaking on slump sale basis	-		(850.00)	
Payments for purchases of Investments	(25,998.70)		(17,999.77)	
Proceeds from Sale of Investments	22,497.13		14,991.35	
Decrease/(Increase) in other bank balances (net)	7.41		(4.58)	
Interest Received	20.72		139.32	
Dividend Received	0.50		0.50	
Net Cash used in Investing Activities		(6,173.90)		(6,136.77)
C. Cash Flow from Financing Activities				
Increase/(decrease) in short-term borrowings (Net)	(6.90)		14.35	
Interest Paid	(120.25)		(507.51)	
Dividend Paid	(5,614.83)		-	
Lease Rent payments	(376.42)		(394.50)	
Net Cash Used in Financing Activities		(6,118.40)		(887.66)
Net Increase / (decrease) in Cash and Cash Equivalents		(1,252.41)		1,208.19
Cash and Cash Equivalents as at the beginning of the period*	2,426.29		636.67	
Exchange differences on restatement of foreign currency cash and cash equivalents	0.59		(1.06)	
Cash and Cash Equivalents as at the end of the period*	1,174.47	(1,252.41)	1,843.80	1,208.19

Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road
Worli, Mumbai - 400 030

Corporate Office:
Cnergy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 5500
+91 22 2431 5331 / 5334
info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

*Cash and Cash Equivalents comprises the following

Particulars	As at September 30, 2021	As at September 30, 2020
Balances with banks	1,163.33	1,392.23
Cash on hand	11.14	29.31
Fixed Deposits with maturity of less than 3 months	-	575.69
	1,174.47	1,997.23
Less : Bank Overdraft	-	153.43
Cash and Cash Equivalents	1,174.47	1,843.80

Note: The Cash Flow Statement is prepared using the "Indirect method" set out in Ind AS 7 - "Statement of Cash Flows".

For J. B. Chemicals & Pharmaceuticals Ltd.

Nikhil Chopra

Chief Executive Officer & Whole-time Director

Date : 11/11/2021

Place : Mumbai

Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road
Worli, Mumbai - 400 030

Corporate Office:
Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 5500
+91 22 2431 5331 / 5334
info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380

Deloitte Haskins & Sells LLP

Chartered Accountants
One International Center
Tower 3, 32nd Floor
Senapati Bapat Marg
Elphinstone Road (West)
Mumbai – 400 013
Maharashtra, India
Tele: + 91 22 6185 4000
Fax: +91 22 6185 4001

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF J. B. CHEMICALS & PHARMACEUTICALS LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **J. B. CHEMICALS & PHARMACEUTICALS LIMITED** ("the Company"), for the quarter and six months ended September 30, 2021 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

EH RKB

**Deloitte
Haskins & Sells LLP**

5. The comparative standalone financial information of the Company for the quarter and six months ended September 30, 2020 prepared in accordance with Ind AS, included in this Statement, have been reviewed by the predecessor auditor. The review report dated November 10, 2020, of the predecessor auditor, on the comparative financial information, expressed an unmodified conclusion.

Our conclusion on the Statement is not modified in respect of this matter.

For DELOITTE HASKINS & SELLS LLP
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



Rajesh K. Hiranandani
Partner
(Membership No.36920)
(UDIN: 21036920AAAAFO3383)

EM

Place: MUMBAI
Date: November 11, 2021



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 2021

(₹ in lakhs)

Sl.No	Particulars	Quarter ended			Half Year ended		Year ended
		30/09/2021	30/06/2021	30/09/2020	30/09/2021	30/09/2020	31/03/2021
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from operations	52,672.69	54,630.13	41,177.85	1,07,302.82	90,140.28	1,89,199.55
2	Other income (Refer Note 5)	1,956.07	1,288.23	818.78	3,244.30	3,072.32	11,188.94
3	Total income (1+2)	54,628.76	55,918.36	41,996.63	1,10,547.12	93,212.60	2,00,388.49
4	Expenses						
	a. Cost of materials consumed	14,707.66	14,787.80	15,204.58	29,495.46	27,862.41	54,216.52
	b. Purchases of stock-in-trade	5,031.75	4,944.75	1,302.57	9,976.50	5,595.11	9,929.08
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,752.04)	(1,209.69)	(4,387.47)	(2,961.73)	(4,829.12)	(1,570.03)
	d. Employee benefits expense (Refer Note 3)	9,521.95	8,875.56	7,302.88	18,397.51	15,457.03	30,597.97
	e. Finance costs	118.44	88.54	169.59	206.98	542.71	719.18
	f. Depreciation and amortization expense	1,539.94	1,747.87	1,714.01	3,287.81	3,410.74	6,735.50
	g. Other expenses	13,695.02	11,401.29	11,181.64	25,096.31	19,665.68	40,389.47
	Total expenses (4)	42,862.72	40,636.12	32,487.80	83,498.84	67,704.56	1,41,017.69
5	Profit before tax (3-4)	11,766.04	15,282.24	9,508.83	27,048.28	25,508.04	59,370.80
6	Tax expenses						
	a. Current tax	2,700.00	3,800.00	2,355.00	6,500.00	6,100.00	13,750.00
	b. Deferred tax	226.05	(48.97)	55.52	177.08	117.20	912.32
	Total tax expense	2,926.05	3,751.03	2,410.52	6,677.08	6,217.20	14,662.32
7	Net Profit after tax (5-6)	8,839.99	11,531.21	7,098.31	20,371.20	19,290.84	44,708.48
8	Other comprehensive income						
	a. Items that will not be reclassified to profit or loss	(211.43)	(212.55)	(461.44)	(423.98)	(611.44)	(1,669.97)
	b. Income tax thereon	53.22	53.49	116.14	106.71	153.89	420.30
	Other Comprehensive income (net of tax)	(158.21)	(159.06)	(345.30)	(317.27)	(457.55)	(1,249.67)
9	Total comprehensive income after tax (7+8)	8,681.78	11,372.15	6,753.01	20,053.93	18,833.29	43,458.81
10	Paid up equity share capital (Face value of ₹ 2 each)	1,545.64	1,545.64	1,545.64	1,545.64	1,545.64	1,545.64
11	Other equity						1,79,100.45
12	Earnings per share (not annualised for the quarter and half year)						
	(1) Basic in ₹	11.44	14.92	9.18	26.36	24.96	57.85
	(2) Diluted in ₹	11.42	14.92	9.18	26.34	24.96	57.85

Notes:

- The above standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 11, 2021. The results of the Company are available for investors at www.jbcpl.com, www.nseindia.com and www.bseindia.com.
- This Statement has been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules, 2015 (as amended) (Ind AS), prescribed under Section 133 of the Companies Act, 2013, and other recognised accounting practices and policies, to the extent applicable.
- During the quarter, the Company has granted 26,04,258 stock options (comprising of 14,51,666 performance based stock options and 11,52,592 time based stock options) to employees and whole-time director(s) of the Company/ subsidiary company. The employee benefit expense for the quarter and half year ended September 30, 2021 includes charge of ₹ 1,316 lakhs towards equity-settled share-based payment transactions in terms of Ind AS 102 - 'Share-based Payment'.
- Subsequent to the quarter, the Company has granted 2,06,463 stock options (comprising of 1,21,095 performance based stock options and 85,368 time based stock options) to employees of the Company/ subsidiary Company.
- Other income for the year ended March 31, 2021 includes ₹ 1,977.24 lakhs being net profit on sale of an industrial land in the state of Maharashtra and ₹ 3,368.66 lakhs being consideration towards sale of one of the Company's product registration along with its marketing authorisation and trademark.
- Based on the internal and external information available up to the date of approval of these financial results by the Board of Directors, the Company continues to believe that the impact of Covid-19 on its business, assets, internal financial controls, profitability and liquidity, both present and future, would be limited and there is no indication of any material impact on the carrying amounts of inventories, tangible and intangible assets, investments, trade receivables and other financial assets. However, concerns of Covid-19 pandemic still continue and hence, the Company continues to follow necessary safety guidelines. The eventual outcome of the impact of the global health pandemic may be different from those estimated as on the date of approval of these financial results and the management will continue to closely monitor the changes to economic conditions in future and its impact on the Company.
- The Company has only one reportable business segment viz. "Pharmaceuticals".
- The figures for the previous period(s) have been re-grouped/reclassified, wherever necessary.

EM RKU

Registered Office:

Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

Corporate Office:

Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

☎ +91 22 2439 5200 / 2439 5500

☎ +91 22 2431 5331 / 2431 5334

@ info@jbcpl.com

🌐 www.jbcpl.com

CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

9 STATEMENT OF STANDALONE ASSETS AND LIABILITIES AS AT SEPTEMBER 30, 2021.

		(₹ in lakhs)	
Particulars		As at September 30, 2021	As at March 31, 2021
		Unaudited	Audited
ASSETS			
(I)	Non-current assets		
	(a) Property, Plant and Equipment	56,407.02	54,227.21
	(b) Capital work-in-progress	706.71	2,556.68
	(c) Goodwill	431.92	431.92
	(d) Other Intangible assets	1,799.25	1,801.25
	(e) Financial Assets		
	(i) Investments	14,606.68	14,587.55
	(ii) Loans	102.49	54.90
	(iii) Other financial assets	529.34	482.38
	(f) Other non-current assets	595.23	106.89
	Total non-current assets	75,178.64	74,248.78
(II)	Current assets		
	(a) Inventories	30,872.48	27,891.28
	(b) Financial Assets		
	(i) Investments	72,965.30	66,497.48
	(ii) Trade receivables	45,472.47	37,410.81
	(iii) Cash and cash equivalents	1,174.47	2,426.29
	(iv) Bank balances other than (iii) above	230.86	216.62
	(v) Loans	44.77	35.59
	(vi) Others	401.00	981.16
	(c) Current Tax Assets (Net)	2,220.44	1,683.83
	(d) Other current assets	8,390.47	8,651.08
	Total current assets	1,61,772.26	1,45,794.14
	Total Assets	2,36,950.90	2,20,042.92
EQUITY AND LIABILITIES			
	Equity		
	(a) Equity Share capital	1,545.64	1,545.64
	(b) Other Equity	1,94,855.79	1,79,100.45
	Total Equity	1,96,401.43	1,80,646.09
(I)	Non-current liabilities		
	(a) Financial Liabilities		
	Lease liabilities	2,080.50	514.14
	(b) Provisions	2,044.03	1,257.14
	(c) Deferred tax liabilities (Net)	6,446.97	6,376.60
	(d) Other non-current liabilities	409.15	493.22
	Total non-current Liabilities	10,980.65	8,641.10
(II)	Current-liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	2,644.10	2,643.28
	(ii) Lease Liabilities	589.22	704.38
	(iii) Trade payables		
	A) Dues to Micro and Small Enterprises	1,217.16	1,309.55
	B) Dues to Other than Micro and Small Enterprises	15,386.21	15,092.41
	(iv) Other financial liabilities	4,741.30	6,563.43
	(b) Other current liabilities	1,068.00	1,377.54
	(c) Provisions	3,319.44	2,461.75
	(d) Current Tax Liabilities (Net)	603.39	603.39
	Total Current Liabilities	29,568.82	30,755.73
	Total Equity and Liabilities	2,36,950.90	2,20,042.92

EM RKK

Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

Corporate Office:
Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500
+91 22 2431 5331 / 2431 5334
info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

10. Standalone Cash Flow Statement for the six months ended September 30, 2021

(₹ in lakhs)

Particulars	For the six months ended September 30, 2021		For the six months ended September 30, 2020	
	Unaudited		Unaudited	
A. Cash Flow from Operating Activities				
Profit before Tax		27,048.28		25,508.04
Adjustments For				
Depreciation and amortisation expense	3,287.81		3,410.74	
Unrealised Foreign Exchange Fluctuation (Net)	117.94		(132.00)	
Interest Expense	183.54		528.91	
Profit/loss on disposal/discard of Property, Plant and Equipment (Net)	(219.07)		70.97	
Profit on sale of Investments measured at FVTPL	(1,489.87)		(941.57)	
Net fair value gain on investments measured at FVTPL	(1,495.49)		(1,758.44)	
Interest Income	(17.88)		(135.21)	
Dividend Income	(0.50)		(0.50)	
Government Grant	(84.21)		(82.66)	
Re-measurement of defined benefit plan	(423.98)		(611.44)	
Excess provision written back	-		(223.09)	
Share based payment expense	1,316.24		-	
Discontinuance of Lease Assets	(14.23)		(7.19)	
		1,160.30		118.52
Operating Profit Before Working Capital Changes		28,208.58		25,626.56
Adjustments For				
Trade and other receivables	(7,560.44)		(6,870.44)	
Inventories	(2,981.20)		(8,884.01)	
Trade, other payables and provisions	409.56		2,960.28	
		(10,132.08)		(12,794.17)
Cash Generated From Operations		18,076.50		12,832.39
Direct Taxes Paid (net)		(7,036.61)		(4,599.77)
Net Cash from Operating Activities		11,039.89		8,232.62
B. Cash Flow from Investing Activities				
Payments for purchase of Property, plant and equipment	(3,451.89)		(2,413.89)	
Proceeds from disposal of Property, plant and equipment	750.93		0.30	
Payment for acquisition of a business undertaking on slump sale basis	-		(850.00)	
Payments for purchases of Investments	(25,998.70)		(17,999.77)	
Proceeds from Sale of Investments	22,497.13		14,991.35	
Decrease/(Increase) in other bank balances (net)	7.41		(4.58)	
Interest Received	20.72		139.32	
Dividend Received	0.50		0.50	
Net Cash used in Investing Activities		(6,173.90)		(6,136.77)
C. Cash Flow from Financing Activities				
Increase/(decrease) in short-term borrowings (Net)	(6.90)		14.35	
Interest Paid	(120.25)		(507.51)	
Dividend Paid	(5,614.83)		-	
Lease Rent payments	(376.42)		(394.50)	
Net Cash Used in Financing Activities		(6,118.40)		(887.66)
Net Increase / (decrease) in Cash and Cash Equivalents		(1,252.41)		1,208.19
Cash and Cash Equivalents as at the beginning of the period*	2,426.29		636.67	
Exchange differences on restatement of foreign currency cash and cash equivalents	0.59		(1.06)	
Cash and Cash Equivalents as at the end of the period*	1,174.47	(1,252.41)	1,843.80	1,208.19

En RKB

Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road
Worli, Mumbai - 400 030

Corporate Office:
Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 5500
+91 22 2431 5331 / 5334
info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

*Cash and Cash Equivalents comprises the following

Particulars	As at September 30, 2021	As at September 30, 2020
Balances with banks	1,163.33	1,392.23
Cash on hand	11.14	29.31
Fixed Deposits with maturity of less than 3 months	-	575.69
	1,174.47	1,997.23
Less : Bank Overdraft	-	153.43
Cash and Cash Equivalents	1,174.47	1,843.80

Note: The Cash Flow Statement is prepared using the "Indirect method" set out in Ind AS 7 - "Statement of Cash Flows".

EN RKB

For J. B. Chemicals & Pharmaceuticals Ltd.

Nikhil Chopra

Chief Executive Officer & Whole-time Director

Date : 11/11/2021

Place : Mumbai

Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road
Worli, Mumbai - 400 030

Corporate Office:
Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 5500
+91 22 2431 5331 / 5334
info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 2021

(₹ in lakhs)

Sl.No.	Particulars	Quarter ended			Half Year ended		Year ended
		30/09/2021	30/06/2021	30/09/2020	30/09/2021	30/09/2020	31/03/2021
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from operations	59,301.17	60,598.85	44,356.43	1,19,900.02	96,584.93	2,04,252.15
2	Other income (Refer Note 6)	1,964.41	1,297.42	839.27	3,261.83	3,108.23	11,238.32
3	Total income (1+2)	61,265.58	61,896.27	45,195.70	1,23,161.85	99,693.16	2,15,490.47
4	Expenses						
	a. Cost of materials consumed	14,721.86	14,792.97	15,207.85	29,514.83	27,868.39	54,238.96
	b. Purchases of stock-in-trade	6,645.22	7,805.31	3,554.20	14,450.53	10,064.44	20,036.65
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(613.62)	(944.02)	(5,379.17)	(1,557.64)	(5,924.38)	(4,125.71)
	d. Employee benefits expense (Refer Note 4)	10,540.31	9,813.98	8,107.14	20,354.29	16,973.74	34,060.09
	e. Finance costs	122.45	93.94	171.57	216.39	546.09	724.12
	f. Depreciation and amortization expense	1,573.37	1,784.89	1,744.64	3,358.26	3,474.03	6,866.55
	g. Other expenses	15,333.25	12,762.38	11,856.50	28,095.63	21,050.71	44,001.27
	Total expenses (4)	48,322.84	46,109.45	35,262.73	94,432.29	74,053.02	1,55,801.93
5	Profit before tax (3-4)	12,942.74	15,786.82	9,932.97	28,729.56	25,640.14	59,688.54
6	Tax expenses						
	a. Current tax	2,744.59	3,942.61	2,447.32	6,687.20	6,254.32	14,220.32
	b. Deferred tax	409.39	(61.73)	93.30	347.66	42.93	615.92
	Total tax expense	3,153.98	3,880.88	2,540.62	7,034.86	6,297.25	14,836.24
7	Net Profit after tax (5-6)	9,788.76	11,905.94	7,392.35	21,694.70	19,342.89	44,852.30
8	Other comprehensive income						
	a. Items that will not be reclassified to profit or loss	(211.43)	(212.55)	(461.44)	(423.98)	(611.44)	(1,669.97)
	b. Income tax thereon	53.22	53.49	116.14	106.71	153.89	420.30
	c. Items that will be reclassified to profit or loss	(570.41)	492.71	(215.57)	(77.70)	200.46	1,283.13
	d. Income tax thereon	-	-	-	-	-	-
	Other comprehensive income (net of tax)	(728.62)	333.65	(560.87)	(394.97)	(257.09)	33.46
9	Total comprehensive income after tax (7+8)	9,060.14	12,239.59	6,831.48	21,299.73	19,085.80	44,885.76
10	Net Profit after tax for the period attributable to:						
	- owners of the company	9,775.31	11,887.32	7,382.28	21,662.63	19,324.44	44,796.36
	- non controlling interest	13.45	18.62	10.07	32.07	18.45	55.94
11	Other comprehensive income for the period attributable to:						
	- owners of the company	(704.89)	318.98	(569.89)	(385.91)	(275.53)	(31.01)
	- non controlling interest	(23.73)	14.67	9.02	(9.06)	18.44	64.47
12	Total comprehensive income after tax attributable to:						
	- owners of the company	9,070.42	12,206.30	6,812.39	21,276.72	19,048.91	44,765.35
	- non controlling interest	(10.28)	33.29	19.09	23.01	36.89	120.41
13	Paid up equity share capital (Face value of ₹ 2 each)	1,545.64	1,545.64	1,545.64	1,545.64	1,545.64	1,545.64
14	Other Equity						1,79,426.84
15	Earnings per share (not annualised for the quarter and half year)						
	(1) Basic in ₹	12.65	15.38	9.55	28.03	25.01	57.96
	(2) Diluted in ₹	12.63	15.38	9.55	28.01	25.01	57.96

Notes:

- The above consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 11, 2021. The results of the Company are available for investors at www.jbcpl.com, www.nseindia.com and www.bseindia.com.
- This Statement has been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules, 2015 (as amended) (Ind AS), prescribed under Section 133 of the Companies Act, 2013, and other recognised accounting practices and policies, to the extent applicable.
- The consolidated financial results of the Holding Company, its wholly owned subsidiaries and a step-down subsidiary ("the Group") have been prepared by applying Ind AS 110 on Consolidated Financial Statements.
- During the quarter, the Holding Company has granted 26,04,258 stock options (comprising of 14,51,666 performance based stock options and 11,52,592 time based stock options) to employees and whole-time director(s) of the Holding Company/ subsidiary company. Employee benefits expense for the quarter and half year ended September 30, 2021 includes charge of ₹ 1,316 lakhs towards equity-settled share-based payment transactions in terms of Ind AS 102 - 'Share-based Payment'.
- Subsequent to the quarter, the Holding Company has granted 2,06,463 stock options (comprising of 1,21,095 performance based stock options and 85,368 time based stock options) to employees of the Holding Company/ subsidiary company.

Registered Office:

Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

Corporate Office:

Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500

+91 22 2431 5331 / 2431 5334

@ info@jbcpl.com

www.jbcpl.com

CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

- 6 Other income for the year ended March 31, 2021 includes ₹ 1,977.24 lakhs being net profit on sale of an industrial land in the state of Maharashtra of the Holding Company, and ₹ 3,368.66 lakhs being consideration towards sale of one of the Holding Company's product registration along with its marketing authorisation and trademark.
- 7 Based on the internal and external information available up to the date of approval of these financial results by the Board of Directors, the Group continues to believe that the impact of Covid-19 on its business, assets, internal financial controls, profitability and liquidity, both present and future, would be limited and there is no indication of any material impact on the carrying amounts of inventories, tangible and intangible assets, investments, trade receivables and other financial assets. However, concerns of Covid-19 pandemic still continue and hence, the Group continues to follow necessary safety guidelines. The eventual outcome of the impact of the global health pandemic may be different from those estimated as on the date of approval of these financial results and the management will continue to closely monitor the changes to economic conditions in future and its impact on the Group.
- 8 The Group has only one reportable business segment viz. "Pharmaceuticals".
- 9 The figures for the previous period(s) have been re-grouped/reclassified, wherever necessary.
- 10 **STATEMENT OF CONSOLIDATED ASSETS AND LIABILITIES AS AT SEPTEMBER 30, 2021.**

(₹ in lakhs)

Particulars	As at September 30, 2021	As at March 31, 2021
	Unaudited	Audited
ASSETS		
(I) Non-current assets		
(a) Property, Plant and Equipment	56,830.46	54,408.82
(b) Capital work-in-progress	706.71	2,556.68
(c) Goodwill	5,745.92	5,745.92
(d) Other Intangible assets	3,239.91	3,210.52
(e) Financial Assets		
(i) Investments	1,309.99	1,290.87
(ii) Loans	102.49	54.90
(iii) Other financial assets	529.34	482.38
(f) Deferred tax assets	701.89	694.30
(g) Other non-current assets	595.23	106.89
Total non-current assets	69,761.94	68,551.28
(II) Current assets		
(a) Inventories	36,306.14	34,744.68
(b) Financial Assets		
(i) Investments	72,965.30	66,497.48
(ii) Trade receivables	47,159.26	38,901.91
(iii) Cash and cash equivalents	3,534.47	2,868.55
(iv) Bank balances other than (iii) above	230.86	216.62
(v) Loans	50.60	48.18
(vi) Others	477.78	996.76
(c) Current Tax Assets (Net)	2,328.48	1,703.78
(d) Other current assets	8,873.31	9,282.28
Total current assets	1,71,926.20	1,55,260.24
Total Assets	2,41,688.14	2,23,811.52
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share capital	1,545.64	1,545.64
(b) Other Equity	1,96,404.97	1,79,426.84
(c) non-controlling interest	393.52	370.51
Total Equity	1,98,344.13	1,81,342.99
LIABILITIES		
(I) Non-current liabilities		
(a) Financial Liabilities		
Lease liabilities	2,276.39	514.14
(b) Provisions	2,044.03	1,257.14
(c) Deferred tax liabilities (Net)	5,913.23	5,676.66
(c) Other non-current financial liabilities		
(d) Other non-current liabilities	409.15	493.22
Total non-current Liabilities	10,642.80	7,941.16

Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

Corporate Office:
Chenergy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500
+91 22 2431 5331 / 2431 5334
info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

(II) Current liabilities		
(a) Financial Liabilities		
(i) Borrowings	2,644.10	3,264.46
(ii) Lease liabilities	626.32	720.19
(iii) Trade payables		
A) Dues to Micro and Small Enterprises	1,217.16	1,309.55
B) Dues to Other than Micro and Small Enterprises	17,842.89	17,382.79
(iv) Other financial liabilities	4,886.70	6,841.31
(b) Other current liabilities	1,145.97	1,420.92
(c) Provisions	3,734.68	2,797.96
(d) Current Tax Liabilities (Net)	603.39	790.19
Total Current Liabilities	32,701.21	34,527.37
Total Equity and Liabilities	2,41,688.14	2,23,811.52

Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

Corporate Office:
Cnergy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500
+91 22 2431 5331 / 2431 5334
@ info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

11. Consolidated Cash Flow Statement for the six months ended on September 30, 2021

(₹ in Lakhs)

Particulars	For the six months ended September 30, 2021		For the six months ended September 30, 2020	
	Unaudited		Unaudited	
A. Cash Flow from Operating Activities				
Profit before Tax		28,729.56		25,640.14
Adjustments For				
Depreciation and amortisation expense	3,358.26		3,474.03	
Unrealised Foreign Exchange Fluctuation (Net)	140.53		25.60	
Interest expense	192.95		532.29	
Profit/loss on disposal/discard of Property, Plant and Equipment (Net)	(225.32)		67.68	
Profit on sale of Investments measured at FVTPL	(1,489.87)		(941.57)	
Net fair value gain on investments measured at FVTPL	(1,495.49)		(1,758.44)	
Interest income	(28.26)		(161.56)	
Dividend income	(0.50)		(0.50)	
Government Grant	(84.21)		(82.66)	
Re-measurement of defined benefit plan	(423.98)		(611.44)	
Excess provision written back	-		(223.09)	
Share based payment expense	1,316.24		-	
Discontinuance of Lease Assets	(14.23)		(7.19)	
Expected credit loss allowance and bad debts written off	50.76		3.93	
		1,296.88		317.08
Operating Profit Before Working Capital Changes		30,026.44		25,957.22
Adjustments For				
Trade and other receivables	(7,689.46)		(7,691.69)	
Inventories	(1,561.46)		(10,026.05)	
Trade, other payables and provisions	426.67		4,103.25	
		(8,824.25)		(13,614.49)
Cash Generated From Operations		21,202.19		12,342.73
Direct Taxes Paid (net)		(7,498.70)		(4,606.12)
Net Cash from Operating Activities		13,703.49		7,736.61
B. Cash Flow from Investing Activities				
Payments for purchase of Property, plant and equipment	(3,552.81)		(2,420.70)	
Proceeds from disposal of Property, plant and equipment	759.54		3.60	
Payment for acquisition of a business undertaking on slump sale basis	-		(850.00)	
Payments for purchases of Investments	(25,998.70)		(17,999.77)	
Proceeds from Sale of Investments	22,497.13		14,991.35	
Decrease/(Increase) in other bank balances (net)	7.41		(4.58)	
Interest Received	31.10		165.67	
Dividend Received	0.50		0.50	
Net Cash used in Investing Activities		(6,255.83)		(6,113.93)
C. Cash Flow from Financing Activities				
Increase/(decrease) in short-term borrowings (Net)	(6.90)		14.35	
Interest Paid	(125.40)		(508.35)	
Dividend Paid	(5,614.83)		-	
Lease Rent payments	(414.02)		(419.30)	
Net Cash Used in Financing Activities		(6,161.15)		(913.30)
Net Increase in Cash and Cash Equivalents		1,286.51		709.38
Cash and Cash Equivalents as at the beginning of the period*	2,247.37		2,575.19	
Exchange differences on restatement of foreign currency cash and cash equivalents	0.59		(1.06)	
Cash and Cash Equivalents as at the end of the period*	3,534.47	1,286.51	3,283.51	709.38

Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road
Worli, Mumbai - 400 030

Corporate Office:
Cnergy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 5500
+91 22 2431 5331 / 5334
info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

*Cash and Cash Equivalents comprises the following

Particulars	As at September 30, 2021	As at September 30, 2020
Balances with banks	3,319.00	2,831.50
Cash on hand	11.63	29.75
Fixed Deposits with maturity of less than 3 months	203.84	575.69
	3,534.47	3,436.94
Less : Bank Overdraft	-	153.43
Cash and Cash Equivalents	3,534.47	3,283.51

Note: The Cash Flow Statement is prepared using the "Indirect method" set out in Ind AS 7 - "Statement of Cash Flows".

For J.B. Chemicals & Pharmaceuticals Ltd.

Nikhil Chopra

Chief Executive Officer & Whole-time Director

Date : 11/11/2021

Place : Mumbai

Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road
Worli, Mumbai - 400 030

Corporate Office:
Cnergy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 5500
+91 22 2431 5331 / 5334
info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM
CONSOLIDATED FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF
J. B. CHEMICALS & PHARMACEUTICALS LIMITED**

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **J. B. CHEMICALS & PHARMACEUTICALS LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter and six months ended September 30, 2021 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:
Parent J. B. Chemicals & Pharmaceuticals Limited

Direct Subsidiaries OOO Unique Pharmaceutical Laboratories; and
Unique Pharmaceutical Laboratories FZE.

Step down Subsidiary Biotech Laboratories (Pty.) Ltd.

Page 1 of 3

Deloitte Haskins & Sells LLP

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, and based on the consideration of the review report of the other auditor referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial information of one subsidiary included in the consolidated unaudited financial results, whose interim financial information reflect total assets of Rs. 13,991.58 Lakhs as at September 30, 2021, total revenues of Rs. 7,662.99 Lakhs and Rs. 14,078.20 Lakhs for the quarter and six months ended September 30, 2021 respectively, total net profit after tax of Rs. 282.51 Lakhs and Rs. 673.68 Lakhs for the quarter and six months ended September 30, 2021 respectively, total comprehensive income of Rs. 282.51 Lakhs and Rs. 673.68 Lakhs for the quarter and six months ended September 30, 2021 respectively and net cash inflows of Rs. 1,950.22 Lakhs for the six months ended September 30, 2021, as considered in the Statement. This interim financial information has been reviewed by another auditor whose report has been furnished to us and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of this matter.

7. The consolidated unaudited financial results include the interim financial information of two subsidiaries which have not been reviewed by their auditors, whose interim financial information reflect total assets of Rs.17,565.63 Lakhs as at September 30, 2021, total revenue of Rs. 1,790.35 Lakhs and Rs. 3,086.30 Lakhs for the quarter and six months ended September 30, 2021 respectively, total net profit after tax of Rs. 37.11 Lakhs and Rs. 12.71 Lakhs for the quarter and six months ended September 30, 2021 respectively, total comprehensive income of Rs. 37.11 Lakhs and Rs. 12.71 Lakhs for the quarter and six months ended September 30, 2021 respectively and net cash outflows of Rs. 54.51 Lakhs for the six months ended September 30, 2021, as considered in the Statement. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management.

EH

RKH

**Deloitte
Haskins & Sells LLP**

8. The comparative consolidated financial information of the Group for the quarter and six months ended September 30, 2020 prepared in accordance with Ind AS, included in this Statement, have been reviewed by the predecessor auditor. The review report dated November 10, 2020, of the predecessor auditor, on the comparative financial information, expressed an unmodified conclusion.

Our conclusion on the Statement is not modified in respect of this matter.

For DELOITTE HASKINS & SELLS LLP
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



Rajesh K. Hiranandani
Partner
(Membership No.36920)
(UDIN: 21036920AAAAFP4425)

EH

Place: MUMBAI
Date: November 11, 2021



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 2021

(₹ in lakhs)

Sl.No	Particulars	Quarter ended			Half Year ended		Year ended
		30/09/2021	30/06/2021	30/09/2020	30/09/2021	30/09/2020	31/03/2021
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from operations	59,301.17	60,598.85	44,356.43	1,19,900.02	96,584.93	2,04,252.15
2	Other income (Refer Note 6)	1,964.41	1,297.42	839.27	3,261.83	3,108.23	11,238.32
3	Total income (1+2)	61,265.58	61,896.27	45,195.70	1,23,161.85	99,693.16	2,15,490.47
4	Expenses						
	a. Cost of materials consumed	14,721.86	14,792.97	15,207.85	29,514.83	27,868.39	54,238.96
	b. Purchases of stock-in-trade	6,645.22	7,805.31	3,554.20	14,450.53	10,064.44	20,036.65
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(613.62)	(944.02)	(5,379.17)	(1,557.64)	(5,924.38)	(4,125.71)
	d. Employee benefits expense (Refer Note 4)	10,540.31	9,813.98	8,107.14	20,354.29	16,973.74	34,060.09
	e. Finance costs	122.45	93.94	171.57	216.39	546.09	724.12
	f. Depreciation and amortization expense	1,573.37	1,784.89	1,744.64	3,358.26	3,474.03	6,866.55
	g. Other expenses	15,333.25	12,762.38	11,856.50	28,095.63	21,050.71	44,001.27
	Total expenses (4)	48,322.84	46,109.45	35,262.73	94,432.29	74,053.02	1,55,801.93
5	Profit before tax (3-4)	12,942.74	15,786.82	9,932.97	28,729.56	25,640.14	59,688.54
6	Tax expenses						
	a. Current tax	2,744.59	3,942.61	2,447.32	6,687.20	6,254.32	14,220.32
	b. Deferred tax	409.39	(61.73)	93.30	347.66	42.93	615.92
	Total tax expense	3,153.98	3,880.88	2,540.62	7,034.86	6,297.25	14,836.24
7	Net Profit after tax (5-6)	9,788.76	11,905.94	7,392.35	21,694.70	19,342.89	44,852.30
8	Other comprehensive income						
	a. Items that will not be reclassified to profit or loss	(211.43)	(212.55)	(461.44)	(423.98)	(611.44)	(1,669.97)
	b. Income tax thereon	53.22	53.49	116.14	106.71	153.89	420.30
	c. Items that will be reclassified to profit or loss	(570.41)	492.71	(215.57)	(77.70)	200.46	1,283.13
	d. Income tax thereon						
	Other comprehensive income (net of tax)	(728.62)	333.65	(560.87)	(394.97)	(257.09)	33.46
9	Total comprehensive income after tax (7+8)	9,060.14	12,239.59	6,831.48	21,299.73	19,085.80	44,885.76
10	Net Profit after tax for the period attributable to:						
	- owners of the company	9,775.31	11,887.32	7,382.28	21,662.63	19,324.44	44,796.36
	- non controlling interest	13.45	18.62	10.07	32.07	18.45	55.94
11	Other comprehensive income for the period attributable to:						
	- owners of the company	(704.89)	318.98	(569.89)	(385.91)	(275.53)	(31.01)
	- non controlling interest	(23.73)	14.67	9.02	(9.06)	18.44	64.47
12	Total comprehensive income after tax attributable to:						
	- owners of the company	9,070.42	12,206.30	6,812.39	21,276.72	19,048.91	44,765.35
	- non controlling interest	(10.28)	33.29	19.09	23.01	36.89	120.41
13	Paid up equity share capital (Face value of ₹ 2 each)	1,545.64	1,545.64	1,545.64	1,545.64	1,545.64	1,545.64
14	Other Equity						1,79,426.84
15	Earnings per share (not annualised for the quarter and half year)						
	(1) Basic in ₹	12.65	15.38	9.55	28.03	25.01	57.96
	(2) Diluted in ₹	12.63	15.38	9.55	28.01	25.01	57.96

Notes:

- The above consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 11, 2021. The results of the Company are available for investors at www.jbcpl.com, www.nseindia.com and www.bseindia.com.
- This Statement has been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules, 2015 (as amended) (Ind AS), prescribed under Section 133 of the Companies Act, 2013, and other recognised accounting practices and policies, to the extent applicable.
- The consolidated financial results of the Holding Company, its wholly owned subsidiaries and a step-down subsidiary ("the Group") have been prepared by applying Ind AS 110 on Consolidated Financial Statements.
- During the quarter, the Holding Company has granted 26,04,258 stock options (comprising of 14,51,666 performance based stock options and 11,52,592 time based stock options) to employees and whole-time director(s) of the Holding Company/ subsidiary company. Employee benefits expense for the quarter and half year ended September 30, 2021 includes charge of ₹ 1,316 lakhs towards equity-settled share-based payment transactions in terms of Ind AS 102 - 'Share-based Payment'.
- Subsequent to the quarter, the Holding Company has granted 2,06,463 stock options (comprising of 1,21,095 performance based stock options and 85,368 time based stock options) to employees of the Holding Company/ subsidiary company.

EM RKB

Registered Office:

Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

Corporate Office:

Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500

+91 22 2431 5331 / 2431 5334

info@jbcpl.com

www.jbcpl.com

CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

- 6 Other income for the year ended March 31, 2021 includes ₹ 1,977.24 lakhs being net profit on sale of an industrial land in the state of Maharashtra of the Holding Company, and ₹ 3,368.66 lakhs being consideration towards sale of one of the Holding Company's product registration along with its marketing authorisation and trademark.
- 7 Based on the internal and external information available up to the date of approval of these financial results by the Board of Directors, the Group continues to believe that the impact of Covid-19 on its business, assets, internal financial controls, profitability and liquidity, both present and future, would be limited and there is no indication of any material impact on the carrying amounts of inventories, tangible and intangible assets, investments, trade receivables and other financial assets. However, concerns of Covid-19 pandemic still continue and hence, the Group continues to follow necessary safety guidelines. The eventual outcome of the impact of the global health pandemic may be different from those estimated as on the date of approval of these financial results and the management will continue to closely monitor the changes to economic conditions in future and its impact on the Group.
- 8 The Group has only one reportable business segment viz. "Pharmaceuticals".
- 9 The figures for the previous period(s) have been re-grouped/reclassified, wherever necessary.
- 10 **STATEMENT OF CONSOLIDATED ASSETS AND LIABILITIES AS AT SEPTEMBER 30, 2021.**

		(₹ in lakhs)	
Particulars	As at September 30, 2021		As at March 31, 2021
	Unaudited	Audited	Audited
ASSETS			
(I) Non-current assets			
(a) Property, Plant and Equipment	56,830.46		54,408.82
(b) Capital work-in-progress	706.71		2,556.68
(c) Goodwill	5,745.92		5,745.92
(d) Other Intangible assets	3,239.91		3,210.52
(e) Financial Assets			
(i) Investments	1,309.99		1,290.87
(ii) Loans	102.49		54.90
(iii) Other financial assets	529.34		482.38
(f) Deferred tax assets	701.89		694.30
(g) Other non-current assets	595.23		106.89
Total non-current assets	69,761.94		68,551.28
(II) Current assets			
(a) Inventories	36,306.14		34,744.68
(b) Financial Assets			
(i) Investments	72,965.30		66,497.48
(ii) Trade receivables	47,159.26		38,901.91
(iii) Cash and cash equivalents	3,534.47		2,868.55
(iv) Bank balances other than (iii) above	230.86		216.62
(v) Loans	50.60		48.18
(vi) Others	477.78		996.76
(c) Current Tax Assets (Net)	2,328.48		1,703.78
(d) Other current assets	8,873.31		9,282.28
Total current assets	1,71,926.20		1,55,260.24
Total Assets	2,41,688.14		2,23,811.52
EQUITY AND LIABILITIES			
Equity			
(a) Equity Share capital	1,545.64		1,545.64
(b) Other Equity	1,96,404.97		1,79,426.84
(c) non-controlling interest	393.52		370.51
Total Equity	1,98,344.13		1,81,342.99
LIABILITIES			
(I) Non-current liabilities			
(a) Financial Liabilities			
Lease liabilities	2,276.39		514.14
(b) Provisions	2,044.03		1,257.14
(c) Deferred tax liabilities (Net)	5,913.23		5,676.66
(c) Other non-current financial liabilities			
(d) Other non-current liabilities	409.15		493.22
Total non-current Liabilities	10,642.80		7,941.16

EM RKU

Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

Corporate Office:
Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500
+91 22 2431 5331 / 2431 5334
info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

(II) Current liabilities		
(a) Financial Liabilities		
(i) Borrowings	2,644.10	3,264.46
(ii) Lease liabilities	626.32	720.19
(iii) Trade payables		
A) Dues to Micro and Small Enterprises	1,217.16	1,309.55
B) Dues to Other than Micro and Small Enterprises	17,842.89	17,382.79
(iv) Other financial liabilities	4,886.70	6,841.31
(b) Other current liabilities	1,145.97	1,420.92
(c) Provisions	3,734.68	2,797.96
(d) Current Tax Liabilities (Net)	603.39	790.19
Total Current Liabilities	32,701.21	34,527.37
Total Equity and Liabilities	2,41,688.14	2,23,811.52

EM RKK

📍 **Registered Office:**
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

📍 **Corporate Office:**
Cnergy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

☎ +91 22 2439 5200 / 2439 5500
☎ +91 22 2431 5331 / 2431 5334
✉ info@jbcpl.com
🌐 www.jbcpl.com
CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

11. Consolidated Cash Flow Statement for the six months ended on September 30, 2021

(₹ in Lakhs)

Particulars	For the six months ended September 30, 2021		For the six months ended September 30, 2020	
	Unaudited		Unaudited	
A. Cash Flow from Operating Activities				
Profit before Tax		28,729.56		25,640.14
Adjustments For				
Depreciation and amortisation expense	3,358.26		3,474.03	
Unrealised Foreign Exchange Fluctuation (Net)	140.53		25.60	
Interest expense	192.95		532.29	
Profit/loss on disposal/discard of Property, Plant and Equipment (Net)	(225.32)		67.68	
Profit on sale of Investments measured at FVTPL	(1,489.87)		(941.57)	
Net fair value gain on investments measured at FVTPL	(1,495.49)		(1,758.44)	
Interest income	(28.26)		(161.56)	
Dividend income	(0.50)		(0.50)	
Government Grant	(84.21)		(82.66)	
Re-measurement of defined benefit plan	(423.98)		(611.44)	
Excess provision written back	-		(223.09)	
Share based payment expense	1,316.24		-	
Discontinuance of Lease Assets	(14.23)		(7.19)	
Expected credit loss allowance and bad debts written off	50.76		3.93	
		1,296.88		317.08
Operating Profit Before Working Capital Changes		30,026.44		25,957.22
Adjustments For				
Trade and other receivables	(7,689.46)		(7,691.69)	
Inventories	(1,561.46)		(10,026.05)	
Trade, other payables and provisions	426.67		4,103.25	
		(8,824.25)		(13,614.49)
Cash Generated From Operations		21,202.19		12,342.73
Direct Taxes Paid (net)		(7,498.70)		(4,606.12)
Net Cash from Operating Activities		13,703.49		7,736.61
B. Cash Flow from Investing Activities				
Payments for purchase of Property, plant and equipment	(3,552.81)		(2,420.70)	
Proceeds from disposal of Property, plant and equipment	759.54		3.60	
Payment for acquisition of a business undertaking on slump sale basis	-		(850.00)	
Payments for purchases of Investments	(25,998.70)		(17,999.77)	
Proceeds from Sale of Investments	22,497.13		14,991.35	
Decrease/(Increase) in other bank balances (net)	7.41		(4.58)	
Interest Received	31.10		165.67	
Dividend Received	0.50		0.50	
Net Cash used in Investing Activities		(6,255.83)		(6,113.93)
C. Cash Flow from Financing Activities				
Increase/(decrease) in short-term borrowings (Net)	(6.90)		14.35	
Interest Paid	(125.40)		(508.35)	
Dividend Paid	(5,614.83)		-	
Lease Rent payments	(414.02)		(419.30)	
Net Cash Used in Financing Activities		(6,161.15)		(913.30)
Net Increase in Cash and Cash Equivalents		1,286.51		709.38
Cash and Cash Equivalents as at the beginning of the period*	2,247.37		2,575.19	
Exchange differences on restatement of foreign currency cash and cash equivalents	0.59		(1.06)	
Cash and Cash Equivalents as at the end of the period*	3,534.47	1,286.51	3,283.51	709.38

EM RKB

Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road
Worli, Mumbai - 400 030

Corporate Office:
Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 5500
+91 22 2431 5331 / 5334
info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

*Cash and Cash Equivalents comprises the following

Particulars	As at September 30, 2021	As at September 30, 2020
Balances with banks	3,319.00	2,831.50
Cash on hand	11.63	29.75
Fixed Deposits with maturity of less than 3 months	203.84	575.69
	3,534.47	3,436.94
Less : Bank Overdraft	-	153.43
Cash and Cash Equivalents	3,534.47	3,283.51

Note: The Cash Flow Statement is prepared using the "Indirect method" set out in Ind AS 7 - "Statement of Cash Flows".

EN RKU

For J.B. Chemicals & Pharmaceuticals Ltd.

Nikhil Chopra

Chief Executive Officer & Whole-time Director

Date : 11/11/2021

Place : Mumbai

Registered Office:

Neelam Centre, B Wing, 4th Floor
Hind Cycle Road
Worli, Mumbai - 400 030

Corporate Office:

Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 5500

+91 22 2431 5331 / 5334

info@jbcpl.com

www.jbcpl.com

CIN: L24390MH1976PLC019380